Embryonic stem cells (ESCs) are the ex vivo equivalent of the epiblast lineage of the blastocyst, and therefore they share the same developmental potential to differentiate into any one of the three primary germ layers: mesoderm, definitive endoderm and ectoderm (Fig. 1) . This developmental pluripotency combined with a high capacity for self-renewal in vitro are the defining features of ESCs. Mouse embryonic stem cells (mESCs) are derived from preimplantation-stage embryos 1, 2 . The progenitor cells that give rise to mESCs reside in the epiblast of the late blastocyst (~4 d post coitum (d.p.c.)) and express several pluripotencyassociated factors, including OCT3/4 (officially known as POU5F1) and NANOG 3 . In addition to their capacity for self-renewal and stable pluripotency in vitro, mESCs have the defining capacity to populate the germline after microinjection into, or aggregation with, host embryos, making mESCs essential tools for genetic engineering 4 . The Nobel prize-winning discovery that genes could be genetically modified in mice by using mESCs was published over 30 years ago, and since then nearly 50,000 genetically modified alleles have been created by individual investigators around the world and by the International Knockout Mouse Consortium (IKMC, http://www.mousephenotype.org/martsearch_ikmc_ project) which endeavors to create null and/or conditional null alleles for every gene in the mouse genome 5, 6 . mESCs are also used for basic research on pluripotency and for the development of stem cell-based therapies as the starting material for directed differentiation of enriched, defined cell types in vitro.
Derivation of mESCs
Despite knowledge of the basic requirements for mESCs to maintain pluripotency, derivation of mESCs remained inefficient, and it was limited to just a few mouse strains for many years 7 . These so-called permissive strains included 129 substrains, as well as the most commonly used inbred mouse strain C57BL/6. Early protocols showed the requirement of leukemia inhibitory factor (LIF) to activate signal transducer and activator of transcription 3 (STAT3), bone morphogenetic protein (BMP) (or serum) and mitotically inactivated feeder layers, preferably mouse embryonic fibroblasts (MEFs), to prevent the differentiation of mESCs in vitro. However, derivation efficiency in permissive strains was at best 30%, as determined by the percentage of embryos giving rise to stable mESC lines 8, 9 . Moreover, in nonpermissive mouse strains, such as CBA, NOD, DBA and others, derivation efficiency was either extraordinarily low or nonexistent 7 . Therefore, for mammalian geneticists who rely on specific inbred strain backgrounds for human disease modeling, genetically engineered alleles created in 129, C57BL/6 or hybrid ES cells required 10-20 backcross generations (up to 2 years) to create the desired genetic background. Moreover, for mammalian species other than the mouse, genetic engineering was simply not possible owing to an inability to derive legitimate ES cells despite considerable effort over many years. Recent advances in site-specific nuclease technologies (e.g., zinc-finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs) and clustered regularly interspersed short palindromic repeats (CRISPRs)/Cas)) are enabling direct, targeted deletion and targeted, sequential gene modifications via pronuclear injection of mouse embryos 10 and other species, including rat 11, 12 . For genetic engineering, these technologies circumvent the need for ES cells. However, the applicability for multifaceted genomic modifications via homologous recombination with large inserts, across a variety of strains, has not yet been demonstrated. and pluripotency has grown, protocols for the efficient derivation of mES cells by promoting or inhibiting the expression of specific genetic pathways were developed. Oct4 (Pou5f1) is a transcription factor that is essential for the maintenance of pluripotency in cells of the ICM, the epiblast and in mES cell lines. Importantly, loss of Oct4 was shown to be a feature of cultured embryos that failed to give rise to stable ES cell lines 14 . On the basis of this discovery, culture conditions that promote Oct4 expression, namely inhibition of the MAP kinase pathway, were introduced. However, successful derivation of mES cells from the recalcitrant strain background, CBA, still required a combination of diapause induction, epiblast excision and inhibition of MEK kinase via PD98059 (ref. 14) . In the context of these modifications to traditional ES cell derivation protocols, derivation efficiency in the CBA strain was ~25%, which is a significant advance for a nonpermissive strain 14 .
The pluripotent ground state and overcoming barriers to mESC derivation
The discovery that self-renewal and pluripotency are intrinsic properties of mESCs was demonstrated by Smith and colleagues 14 , who showed that the inhibition of MEK/ERK and glycogen synthase kinase-3 (GSK3) signaling (three inhibitors (3i): PD184352, PD173074/SU5402 and CHIR99021, respectively) were together sufficient, combined with activation of STAT3 by LIF (3i/LIF), to promote the pluripotent ground state of emergent ESCs from mice and from rats [15] [16] [17] . These laboratories went on to show that the inhibition of FGF receptor signaling is dispensable in the context of more potent inhibition of MEK signaling (2i: CHIR99021 to inhibit GSK3β and PD0325901 to inhibit MEK1/2) 16 . Both 3i/LIF and, subsequently, 2i/LIF culture conditions have since been successfully applied for efficient (50-70%) derivation of germline-competent mESCs from recalcitrant strains such as NOD, CBA and DBA [18] [19] [20] [21] . Moreover, these culture conditions have been used to successfully derive germline-competent rat ESCs from rat embryos 16, 17 , which is an accomplishment that quickly led to the creation of the first rat gene knockout by homologous recombination in rESCs 22 . The successful derivation of ESCs from recalcitrant strains and from rat by using 2i/LIF culture conditions suggests that emergent ESCs from these strains or species are unable to maintain a pluripotent ground state under traditional ESC culture conditions (serum + LIF). In fact, it was later shown that, unlike emergent ESCs from permissive strain background (e.g., 129), emergent ESCs from nonpermissive strain backgrounds (e.g., NOD) are unstable and differentiate to a more advanced epiSC (postimplantation epiblast stem cell) state, which has been termed a primed pluripotent state, in the absence of exogenously provided inhibitors of ERK signaling 23 .
Although the basis of strain and species recalcitrance to ESC derivation is not yet fully understood, these results suggest that inhibition of the pathways responsible for differentiation of ICM epiblast cells to postimplantation epiblast cells might be sufficient to overcome barriers to mESC derivation in all inbred strain backgrounds. This new model of the pluripotent, ground state of ESCs is an important advance in our understanding of early lineage commitment, and it has informed our mESC derivation protocol, which is highly efficient, regardless of strain background.
Experimental design
We previously published efficient derivation of germline-competent mESC lines from the recalcitrant strain DBA/2J (ref. 20) . Crucial to the success of this protocol was the exclusion of serum during the outgrowth phase, combined with the inhibition of MEK/ERK (1i: PD98059) signaling during the outgrowth phase and during subsequent culture of emergent ES cell lines (3i: CHIR99021, PD173074 and PD0325901). As published data later showed the FGF receptor inhibitor PD173074 to be dispensable and the MEK inhibitor PD98059 to be redundant, in the context of the more potent MEK inhibitor PD0325901 (ref. 16 ), our current protocol uses the now standard 2i combination (CHIR99021 and PD0325901) to achieve the same exogenous inhibition with simpler media formulae.
Our protocol begins with the collection and culture of late blastocyst-stage embryos, which can be generated by natural mating or by in vitro fertilization. These embryos are then cultured in derivation medium to allow for ICM outgrowth. Unlike traditional ESC derivation medium, which contains serum, our derivation medium uses serum replacement in the form of an artificial serum replacement or, in the case of nonpermissive strain backgrounds, we use defined serum-free Primitive endoderm (PrE) Gata6, Sox17, Gata4, Sox7
Pluripotent epiblast (Epi) Nanog Figure 1 | Overview of preimplantation development in mice. The pre-epiblast lineage in the early embryo is defined by lineage-restricted expression of the Oct3/4, Nanog and Gata6 genes. As early lineage specification proceeds, the pluripotent epiblast lineage is defined by Nanog expression. The epiblast lineage will give rise to all three definitive germ layers of the embryo-proper, namely all somatic cells and germ cells, and it is the population from which mESCs are derived. mESC cell lines retain the developmental potential of the epiblast lineage, and as such they can contribute to all three germ layers and the germ line of host blastocyst-or morula-stage embryos.
medium 24 . The exclusion of serum from the derivation medium was previously shown to promote mESC derivation efficiency 9, 25 , and we have found that it promotes NANOG expression in ICM outgrowths (Fig. 2) . NANOG, which is essential for the acquisition and maintenance of pluripotency, is a biomarker of mESC progenitor cells and is a more reliable readout of cell potency than OCT3/4 (refs. 14,26). Upon ICM disaggregation, incipient mESC lines are cultured either in traditional ESC medium + 2i/LIF (variant A; see Step 10A) or in defined serum-free medium + 2i/LIF (as described by Silva et al. 18 , Ying and Smith 24 and this protocol, variant B (Step 10B)). We and others have found the latter culture conditions to be essential for robust derivation of ES cell lines from the recalcitrant NOD and its derivative strains (NSG and NRG) ( Table 1) 19 . Although the original defined, serum-free + 2i/LIF conditions were created for feeder-free derivation and culture, feeder layers improve derivation efficiency, promote colony attachment Mitotic inactivation of MEFs using mitomycin C Grow MEFs until they are confluent, and then replace the medium with fresh medium containing 10 µg/ml mitomycin C. Return the plates to the incubator for 2-3 h. Wash the MEFs extensively (two or three times) with PBS, collect them using 0.05% (wt/vol) trypsin-EDTA and then count the cells. Resuspend the cells in cryopreservation medium at a concentration of ~1 × 10 7 cells per ml, quickly divide the suspension into 1-ml aliquots in cryovials and temporarily store the aliquots at −80 °C in a CoolCell LX or an equivalent container, which will allow for an optimum freeze rate of −1 °C per minute. Transfer the frozen cells to liquid nitrogen storage within 1 week. MEFs can be stored in liquid nitrogen indefinitely. To prepare feeder layers, thaw one vial and resuspend it in ~100 ml of MEF medium and plate it onto gelatinized dishes at a density of 1 × 10 5 cells per cm 2 .
Mitotic inactivation of MEFs using -irradiation Expose confluent
MEFs to γ-rays and achieve an exposure of 5,000-10,000 rads. Collect and resuspend the MEFs in cryopreservation medium, as described for mitomycin-treated MEFs. EQUIPMENT SETUP Mouth pipette Heat the center of a glass, calibrated micropipette over a gas microburner, stretch the pipette by hand and then break the pipette in the center. Assess the broken end under a stereomicroscope. Keep only those pipettes that are thin, even and that have a diameter 1.5-2× that of a standard mouse blastocyst. Insert the pulled pipette into an aspirator apparatus (Fig. 3) . If mouth pipetting is not possible or desirable, micropipette aids are commercially available (e.g., Drummond, Captrol III, cat. no. 3-000-752), and they can be used in place of the mouth-controlled aspirator apparatus shown in Figure 3 . Gelatinized plates Gelatinize all tissue culture plates and dishes to promote cell attachment. Pipet a sufficient amount of 0.1% (wt/vol) gelatin to cover the surface of a tissue culture-treated plate. Incubate the plate for at least 15 min at room temperature (20-25 °C 4| With a 5-ml syringe, collect 4 ml of M2 medium and attach a 27-G needle. While securing the uterine horn with forceps, insert the needle and flush the uterine horn with 2 ml of M2 medium into a Petri dish. Repeat this process with the second uterine horn (Fig. 3) .
5| By using a mouth pipette or alternative micropipetting aid, collect the flushed embryos and wash through several drops of M2 before placing into a final drop of M2 medium (Fig. 3) .
6|
If embryos are not fully expanded, blastocysts with clearly discernible blastocoels ( Fig. 1, E 4 .0), culture the embryos overnight in a 35-mm dish of KSOM at 37 °C, 5% CO 2 . If blastocysts are fully expanded at the time of collection, continue to
Step 5.  crItIcal step If the blastocysts are not fully expanded when proceeding to Step 5, the percentage of embryos that hatch and attach to the feeders layers after plating may be very low (>50%). Embryos may also be collected at 3.75 d.p.c. to ensure a higher percentage of expanded blastocysts.  crItIcal step Traditional mESC derivation protocols recommend the removal of the zona pellucida before plating. Although this step is unnecessary (viable embryos will hatch naturally under appropriate culture conditions) and can lead to embryo loss, there are some scenarios that may warrant zona removal. For a detailed protocol on zona removal by using acid Tyrode's solution, see Nagy et al. 27 .
plating and early culture • tIMInG 7-9 d 7| By using a mouth pipette (or alternative micropipette aid), plate blastocysts in either KOSR ES medium (see Step 10A) or serum-free ES medium (see Step 10B), one blastocyst per well of a four-well MEF feeder plate (Fig. 4, day 1) containing the appropriate medium for derivation.
8|
Incubate the plates at 37 °C, 5% CO 2 . Do not disturb the plates for 48 h to allow for the blastocysts to hatch and attach to the feeder layer. The majority (80-90%) of blastocysts should hatch and attach to the feeder layer. On day 3 after plating, replace half the medium with fresh medium, by using either KOSR ES medium or serum-free ES medium depending on the desired experimental variant (Step 10A or Step 10B). Continue to feed the cells in this manner every other day until disaggregation. After the initial 48 h of incubation, monitor the growth of the outgrowth under a microscope daily (Fig. 4 , days 2 and 3). If outgrowths are prominent 1 week after plating, proceed to the next step. If not, wait for 1 or 2 more days before proceeding to Step 9. Do not allow the outgrowths to grow so large that the center becomes dark. (Note that dark areas in outgrowths shown in Figure 2 are also depleted of NANOG). ? trouBlesHootInG
9| Disaggregate outgrowths mechanically (option A) or enzymatically (option B).
(a) Mechanical disaggregation (i) By using a mouth pipette, transfer the outgrowth onto a new feeder-covered four-well plate in either FBS ES medium (for variant A;
Step 10A) or serum-free ES medium (for Step 10B). (Fig. 5) . If poor morphology persists after the first two passages, the incipient ES cell line may be unstable. Expect variable growth rates among emergent lines and be aware that unusually rapid growth could be indicative of karyotypic instability (for example, trisomy for chromosome 8 often results in unusually rapid growth in mESCs). In addition, be alert for signs of deterioration, which include vacuolated cytoplasm, detachment of cells from colonies and cellular debris in the medium. If deterioration continues through passages, discard the cell line. Finally, be aware of signs of contamination, including sudden change in pH, turbidity, small round particles (yeast) and filaments (fungi). (vi) Centrifuge the tube for 5 min at 150g at room temperature. Resuspend the pellet in 2.5 ml of serum-free ES medium, creating a single-cell suspension through gentle trituration.
11|
Continue to culture the cells, replacing the medium with the appropriate medium (FBS ES medium for variant A and serum-free medium for variant B), and observe the cells daily. Once 70% confluency is reached (2-3 d later), passage cells 1:4 onto a 100-mm feeder-covered dish. Alternatively, if genotyping is required, cells can instead be passaged onto two 60-mm dishes, setting aside one for genotyping (Step 19C).
? trouBlesHootInG
12|
Freeze some of the cells in culture when they reach 70% confluency. Change the medium the morning before a freeze to minimize stress on the cells. Follow the passaging protocol in
Step 10 above and resuspend in 1 ml of the appropriate medium (FBS ES medium for variant A and serum-free medium for variant B). Count the cells by using either a manual or automatic cell counter. Centrifuge the cells for 5 min at 150g at room temperature. Resuspend the cells in cryopreservation medium at a concentration of 3 × 10 6 cells per ml. Add 1 ml of medium per cryovial. Transfer each vial to a CoolCell (or other container that will allow for a cool rate of −1 °C/min) and place it at −80 °C. After 24 h, transfer the cells to liquid nitrogen. The frozen cells are now at P3-P4 (see Step 9B(vi) regarding passage number assignment), depending on whether the initial disaggregation (Step 9) was enzymatic (P4) or mechanical (P3).  crItIcal step It is best practice to freeze cells as soon as possible to create a stock of ultra-low-passage vials.
? trouBlesHootInG  pause poInt Cells can now be stored in liquid nitrogen indefinitely. Carefully maintain these stocks and plan subsequent thaws and expansions to preserve low-passage vials.
esc characterization • tIMInG ~3 weeks 13| One day before seeding ES cells, thaw and plate mitotically inactivated MEFs. For the full characterization of one cell line, two 60-mm dishes and six wells on a 12-well plate are needed. In addition, for a full characterization, two gelatinized 60-mm plates without feeders are needed. Incubate MEF feeder plates or dishes at 37 °C, 5% CO 2 .
14|
The day after MEF plating, remove a vial of frozen ESCs from liquid nitrogen. Place the vial in a 37 °C water bath until the cells begin to thaw.
15|
Sterilize the vial with 70% (vol/vol) ethanol and then transfer the cells to 10 ml of prewarmed (37 °C) medium in a 15-ml conical tube.
16|
Centrifuge the cells for 5 min at 150g at room temperature.
17|
Resuspend the pellet in 5 ml of medium and create a single-cell suspension by gentle trituration with a serological pipette. Plate the cells onto a 60-mm MEF feeder plate.
18| Once the cells have reached 70% confluency, trypsinize the cells as detailed in
Step 10, resuspend them in 4 ml of ES medium and divide them into four 1-ml aliquots in separate 15-ml conical tubes.
19|
Seed the cells according to the instructions below and proceed with immunolabeling for markers of pluripotency (option A), mitotic chromosome counting (option B), DNA extraction for genotyping (option C) and pathogen testing (option D). We recommend that users perform all of these options to enable complete mESC characterization. • tIMInG 1 h (i) Take 1 ml of the cell suspension and add an additional 4 ml of ES medium. Seed the suspension onto a 60-mm gelatinized dish.  crItIcal step For optimal and accurate mESC-specific SNP genotyping, it is important to exclude feeders. (v) Resuspend the cells in the used medium, by dividing them into three tubes: 0.5 ml for bacterial testing, 2 ml for fungal testing and 2.5 ml for Mycoplasma testing. (vi) For bacterial testing, add the 0.5-ml aliquot from
Step 19D(iv) to 4. 23| Inactivate the trypsin and add an additional 3 ml of medium to the dish.
24|
Return the cells to the incubator for 20 min to allow feeder cells to settle to the bottom of the dish.
25|
Carefully remove the supernatant to a 15-ml conical tube.
26|
Centrifuge the mixture for 5 min at 150g at room temperature.
27| Wash the cells with PBS.
28|
29|
Resuspend the cells in 1 ml of medium buffered with 10 mM HEPES.
30| Deliver cells to the microinjection facility. Request host embryos from a strain that will allow for determination of mESC contribution by coat color, as depicted in Figure 8 . For a review of mouse coat-color loci, see Jackson 30 .  crItIcal step Microinjection of mESCs into host blastocyst embryos requires specialized equipment and expertise and is usually provided by a core facility. For laboratories interested in establishing in-house microinjection/chimera production capability, detailed protocols are available from a variety of sources, including Nagy et al. 27 ).
31|
Collect the relevant data for 50-100 injections, as shown in table 2. Generate ~20 offspring per chimera, assess GLT by using coat color as a guide (Fig. 8) and reference the data shown in 
